CN107260731A - One kind is used to prevent and treat dog duct inflammation, dermopathic pharmaceutical composition and its application - Google Patents
One kind is used to prevent and treat dog duct inflammation, dermopathic pharmaceutical composition and its application Download PDFInfo
- Publication number
- CN107260731A CN107260731A CN201710285398.1A CN201710285398A CN107260731A CN 107260731 A CN107260731 A CN 107260731A CN 201710285398 A CN201710285398 A CN 201710285398A CN 107260731 A CN107260731 A CN 107260731A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- dog
- duct
- application
- dermopathic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of for preventing and treating dog duct inflammation, dermopathic pharmaceutical composition and its application.Contain 0.005~0.2g of Berberine hydrochloride in per 100ml solution, dyclonine hydrochloride 0.2g~2.0g, solvent is the aqueous solution that volumetric concentration is 20%~60% propane diols.Pharmaceutical composition drug effect of the present invention is high, can reduce treatment dog otitis externa, dermopathic time and treatment number of times, reduce the pain of animal, increase animal welfare.
Description
Technical field
The invention belongs to field of veterinary, and in particular to one kind is used to prevent and treat by bacterium, fungus-caused dog duct inflammation, skin
The pharmaceutical composition of skin disease.
Background technology
Dog duct inflammation refers to the acute or chronic inflammation of dog outer course epithelium, and occur together auricle disease or tympanitis sometimes.It is main
It is ear itch, auricle and duct erythema to want symptom, and ear endocrine is excessive and has peculiar smell, may be suppurated when serious and send evil
It is smelly, or even the inaccessible duct of hyperplasia.Sick dog anorexia, wiping ear of shaking the head again and again, cause auricular concha to be scratched, abrade, bleeding or hemotoncus, on
Skin festers, even the serious consequence such as dysacousis.Dog skin disease refers to the inflammation damnification of dog skin texture, is that one kind of dog is normal
See disease, although this disease will not cause dog dead the short time, the outward appearance for suffering from dog can be influenceed, the ornamental value and economy of dog can be reduced
Value, this disease distribution is wide, and there is generation all parts of the country.
Cause the scorching factor of dog duct a lot, bacterium, fungi and parasitic infection are all the important originals for causing dog otitis externa
Cause.Wherein bacterium mainly has staphylococcus aureus, Escherichia coli, proteus etc.；Fungi mainly has chlosma, yeast
Deng；Dog skin disease mainly has pyoderma, dermatomycosis, eczema, causes dermatitis etc..There are some researches show skin disease accounts for dog disease
20%, its course of disease is longer, and pathogenic factor is complicated.Secondly it is barber's itch based on being infected in fungal dermatopathy with microsporum canis
Trichophyta and Microsporum gypseum, bacterial dermatitis (pyoderma) are main as caused by bacterium infection；Intermediate Uveitis ball
Bacterium is one of most commonly seen pathogenic bacteria.
Therefore, dog duct inflammation Main Pathogenic Bacteria concentrates on bacillary, fungoid, sometimes caused by single factors, greatly
Majority is mixed infection, therefore can be effectively treated mixing with antimycotic, antibacterial, antipruritic while treated during treatment and be felt
Dye, reduces dog itch pain, effect is better than in the market merely using the single preparations of ephedrine such as antimycotic, antibacterial, antipruritic.For dog duct
Inflammation, domestic to be treated mostly using glucocorticoid, hydrocortisone vinegar propyl ester, Fluocinonide, dexamethasone, acetic acid
Bo Nisong, triamcinolone, clinically abuse corticosteroid formulations phenomenon and also compare many, although its drug effect is really, easily
Dependence is produced, prolonged application is also easy to produce atrophoderma.Pruritis can be mitigated rapidly using local anesthetic, reduced because of scabies
Itching causes duct inflammation, skin disease to be difficult to cure problem, there is antimycotic, antibacterial action again, removes pathogenic bacteria, reaches and treat both principal and secondary aspect of disease
Effect, and be not likely to produce dependence, atrophoderma will not be caused, can be used for a long time.
The content of the invention
For currently in treatment therapeutic domain present in bacterium, fungus-caused duct inflammation, dermopathic medicine
It is single, the problem of can not treat both principal and secondary aspect of disease, present invention aims at provide a kind of to be used to prevent and treat scorching by bacterium, fungus-caused duct
Disease, dermopathic pharmaceutical composition, the pharmaceutical composition to by bacterium, fungus-caused duct inflammation, dermopathic curative effect it is high,
Preventing and treating spectrum is wide and can meet duct inflammation, the demand of skin disease long-term treatment with antipruritic analgesic.
Realize that technical scheme is as follows：
A kind of pharmaceutical composition for being used to prevent and treat dog otitis externa of the present invention, its constituent and its ratio are：It is molten per 100ml
Contain 0.005~2.0g of Berberine hydrochloride, dyclonine hydrochloride 0.2g~2.0g in liquid, the aqueous solution of propane diols 20%~60% is
Solvent
It is preferred that, the above-mentioned pharmaceutical composition for being used to prevent and treat dog otitis externa, the ratio containing Berberine hydrochloride described in it
Contain Berberine hydrochloride 0.01g in preferably per 100ml solution.
It is preferred that, the above-mentioned pharmaceutical composition for being used to prevent and treat dog otitis externa, the ratio containing dyclonine hydrochloride described in it
Contain dyclonine hydrochloride 0.5g in the preferably every 100ml solution of example.
It is preferred that, it is above-mentioned to be used to prevent and treat by bacterium, fungus-caused duct inflammation, dermopathic pharmaceutical composition, its institute
The water-soluble liquid proportional containing propane diols stated is preferably the aqueous solution of propylene glycol that volumetric concentration is 25%~35%.
It is preferred that, it is above-mentioned to be used to prevent and treat by bacterium, fungus-caused duct inflammation, dermopathic pharmaceutical composition, its group
It is into composition and its ratio：Contain Berberine hydrochloride 0.01g, dyclonine hydrochloride 0.5g, 30% propane diols in per 100ml solution
The aqueous solution is solvent.
It is preferred that, it is above-mentioned to be used to prevent and treat by bacterium, fungus-caused duct inflammation, the formulation of dermopathic pharmaceutical composition
For auristilla, spray or other externally used solution agent.
It is preferred that, it is above-mentioned be used for prevent and treat by bacterium, fungus-caused duct inflammation, dermopathic pharmaceutical composition drop ear
The preparation method of agent, comprises the following steps：
Proportionally Berberine hydrochloride, dyclonine hydrochloride are dissolved in aqueous solution of propylene glycol, stirring 15min to whole
Dissolving, plus purified water adjusts Ph values by 10% hydrochloric acid solution of mass concentration to 2.0-4.0 in right amount, plus purified water is to 100L.Stir
Mix 15min it is uniform after, it is after the assay was approved, filling to produce.
The application of pharmaceutical composition of the present invention
Application of the aforementioned pharmaceutical compositions on preventing and treating dog otitis externa medicine is prepared.
Treatment is by bacterium, fungus-caused duct inflammation：Lift have sharp ears, extruding compound dyclonine auristilla 2-4 times makes
Decoction is full of duct.Gently rub by vertical duct for several times, can hear that the liquid sound is preferred, then use soft paper sheets gentle aspiration
The liquid and dirt of floating.Residual medicine is not minded yet, appoints animal voluntarily to shake the head and throws away.1 time a day.
Described pharmaceutical composition is preventing and treating dermopathic application.Including following steps：Hair is separated, by liquid medicine jet
On pars affecta skin, to complete wetting.
The invention has the advantages that and beneficial effect：(1), pharmaceutical composition of the present invention is to by bacterium, fungus-caused
Duct inflammation cure rate is treated bacterium, fungus-caused duct inflammation comparison medicine Compoud Clotrimazole and controlled up to 93.2%
More rate is only 85.3%, by bacterium, fungus-caused skin disease cure rate up to 71.8%.And treat dog skin disease hydrogenation can
Loose vinegar propyl ester spray cure rate is only 55.2%, and there were significant differences for both prevention effects.(2), pharmaceutical composition of the present invention can
Antipruritic analgesic, can be treated both principal and secondary aspect of disease with antibacterial antifungal again, can for a long time be treated, be overcome caused by glucocorticoid medicine
The shortcoming of drug dependence and atrophoderma.(3), pharmaceutical composition drug effect of the present invention is high, can reduce treatment dog otitis externa when
Between and treatment number of times, reduce animal pain, increase animal welfare.
Embodiment
The preferably embodiment to the present invention is described in further detail below：
Embodiment 1
0.2g dyclonine hydrochlorides, 0.005g Berberine hydrochlorides are weighed respectively, are dissolved in the propane diols water of volumetric concentration 30%
In solution 90ml, 15min is to whole dissolvings, plus purified water for stirring, with the hydrochloric acid solution of mass concentration 10% adjust in right amount pH value to
3.0, plus purified water is to 100L.It is filling to produce after stirring 15min is uniform.
Embodiment 2
0.5g dyclonine hydrochlorides, 0.01g Berberine hydrochlorides are weighed respectively, are dissolved in the water-propylene glycol of volumetric concentration 40%
In liquid 90ml, 15min is to whole dissolvings, plus purified water for stirring, with the hydrochloric acid solution of mass concentration 10% adjust in right amount pH value to
3.0, plus purified water is to 100L.It is filling to produce after stirring 15min is uniform.
Embodiment 3
1.0g dyclonine hydrochlorides, 0.1g Berberine hydrochlorides are weighed respectively, are dissolved in the water-propylene glycol of volumetric concentration 30%
In liquid 90ml, 15min is to whole dissolvings, plus purified water for stirring, with the hydrochloric acid solution of mass concentration 10% adjust in right amount pH value to
3.0, plus purified water is to 100L.It is filling to produce after stirring 15min is uniform.
Embodiment 4
1.5g dyclonine hydrochlorides, 0.5g Berberine hydrochlorides are weighed respectively, are dissolved in the water-propylene glycol of volumetric concentration 30%
In liquid 90ml, 15min is to whole dissolvings, plus purified water for stirring, with the hydrochloric acid solution of mass concentration 10% adjust in right amount pH value to
3.0, plus purified water is to 100L.It is filling to produce after stirring 15min is uniform.
Embodiment 5
2.0g dyclonine hydrochlorides, 1.0g Berberine hydrochlorides are weighed respectively, are dissolved in the water-propylene glycol of volumetric concentration 40%
In liquid 90ml, 15min is to whole dissolvings, plus purified water for stirring, with the hydrochloric acid solution of mass concentration 10% adjust in right amount pH value to
3.0, plus purified water is to 100L.It is filling to produce after stirring 15min is uniform.
Embodiment 6
2.0g dyclonine hydrochlorides, 2.0g Berberine hydrochlorides are weighed respectively, are dissolved in the water-propylene glycol of volumetric concentration 60%
In liquid 90ml, 15min is to whole dissolvings, plus purified water for stirring, with the hydrochloric acid solution of mass concentration 10% adjust in right amount pH value to
3.0, plus purified water is to 100L.It is filling to produce after stirring 15min is uniform.
Embodiment 7
Curative effect contrast test
By dyclonine hydrochloride made from embodiment 1, embodiment 2, embodiment 3, embodiment 4, embodiment 5, embodiment 6 and
The compound clotrimazole that Berberine hydrochloride ester formulation (correspondingly abbreviation test group 1,2,3,4,5,6 individually below) and market are bought is soft
Cream (clotrimazole, celestone-V, gentamicin sulphate) (hereinafter referred to as control group) is applied to caused by dog bacterial fungus
Duct is scorching.
The selection of experimental animal：Selection ear in have erythema, waxy secretion, the dog of otitis externa, through ear swab cytology
Detection has fungi or a bacterium infection, and excludes and used the fungus-caused duct inflammation of other drugs, non-bacterial before experiment, have
The dog of infectious disease and anaphylactia.Experimental animal is grouped：Every group of 20 dogs, body weight 5~15 kilogram 15,15 kilograms of body weight with
On dog 5.And each group experimental animal body condition is compared, to verify its comparativity, in on-test, examined using card side
Test the mass parameter group that (variety classification, sex, Types of otitis externa, past medical history, otitis externa spread situation, clinical symptoms and referred to
Mark, microorganism count) it is compared, it is ensured that experimental animal ear infections state and degree difference less, in therapeutic process, are used
Variance analysis is compared to clinical indices in group and microorganism count.
Control group：Before ear infections treatment, it should thoroughly remove external ear and duct and dry, it is proposed that except being gone using clean ear water
Come material, chip, the secretion of accumulation etc., the superfluous hairs of external ear area for treatment should give removal, appropriate massage after medication
To ensure drug distribution.It is secondary daily, stay the dog below 5 kilograms of effect 7 days (must not exceed 7 days)：Each ear drop 2 of suffering from drips 5-15 public affairs
The dog of jin：It is each to suffer from the dog that ear drop 4 drips more than 15 kilograms：Each ear drop 8 of suffering from is dripped
Test group：Lift have sharp ears, extruding compound dyclonine auristilla 2-4 times makes decoction be full of duct.Gently rub by vertical
Straight duct can hear that the liquid sound is preferred for several times, the liquid and dirt then floated with soft paper sheets gentle aspiration.To residual
Medicine is not minded yet, is appointed animal voluntarily to shake the head and is thrown away.1 time a day, at least it is used in conjunction 7 days.
Result of the test is as shown in table 1：
Table 1
As a result show：Compared with control group, the compound dyclonine auristilla preparation of the embodiment of the present invention 2,3,4,5,6 is controlled
Therapeutic effect is substantially better than Compoud Clotrimazole, and each group difference of test group less, is better than control group, and compound Dacroment
Peaceful auristilla is easy to use, and side effect is considerably less than control group, therefore according to drug effect, economy, adverse reaction, preferred embodiment
2。
Embodiment 8
Curative effect contrast test
By dyclonine hydrochloride made from embodiment 1, embodiment 2, embodiment 3, embodiment 4, embodiment 5, embodiment 6 and
The hydrocortisone vinegar third that Berberine hydrochloride spray (correspondingly abbreviation test group 1,2,3,4,5,6 individually below) and market are bought
Ester spray (hereinafter referred to as control group) is applied to dog treating for skin disease, the selection standard of clinical test dog：Dermopathic clinic
Be presented with erythema, itch, papule depilation, purulence rash, incrustation, scurf, through microscopy or laboratory cultures be accredited as bacterial dermatosis,
Fungal dermatopathy, clinical symptoms evaluation integration difference less, and exclude experiment before used other drugs, non-bacterial fungi
Caused skin disease, the dog for having infectious disease and anaphylactia.Animal packet：Each group animal has 20,5~15 kilograms of body weight
15, dog of the body weight more than 15 kilograms 5, and each group experimental animal body condition is compared, to verify its comparativity, in experiment
During beginning, using Chi-square Test mass parameter (variety classification, sex, Types of otitis externa, past medical history, the scytitis group
Spread situation, clinical symptoms index, microorganism count) it is compared, it is ensured that experimental animal skin infection state and degree difference
Less, in therapeutic process, clinical indices in group and microorganism count are compared using variance analysis.
Comparison therapy effect：
Control group：Before use, first shower nozzle is threaded onto on bottle.Shower nozzle is pressed at affected part about 10cm and is sprayed on affected part., with hydrogen
Change cortisone vinegar propyl ester meter.The daily μ g of skin area 1.52 every square centimeter, equivalent to the square area in 10cm × 10cm
It is interior to spray 2 times.Medication daily 1 time, is used in conjunction 7.
Test group：Hair is separated, by liquid medicine jet on pars affecta skin, to complete wetting, 1 time a day, successive administration 7 days,
7th day, the 14th day observation maintenance result.(this product is sprayed 6 times in every square decimeter of skin affected part)
Result of the test is as shown in table 2：
Table 2
As a result show：Compared with control group, the compound dyclonine spray preparation for treating of the embodiment of the present invention 2,3,4,5,6
Effect is substantially better than hydrocortisone vinegar propyl ester spray, and less, therapeutic equivalence is much better than pair the difference of embodiment 1,2,3,4,5,6
According to medicine group, thus according to drug effect, economy, adverse reaction, drug solution stability, preferred embodiment 2.
Above content is to combine specific preferred embodiment further description made for the present invention, it is impossible to assert
The specific implementation of the present invention is confined to these explanations.For general technical staff of the technical field of the invention,
On the premise of not departing from present inventive concept, some simple deduction or replace can also be made, should all be considered as belonging to the present invention's
Protection domain.
Claims (8)
1. a kind of pharmaceutical composition, it is characterised in that contain 0.005~0.2g of Berberine hydrochloride in per 100ml solution, hydrochloric acid reaches
Cronin 0.2g~2.0g, solvent is the aqueous solution that volumetric concentration is 20%~60% propane diols.
2. pharmaceutical composition as claimed in claim 1, it is characterised in that the formulation of the composition uses auristilla and spraying
One kind in agent.
3. a kind of method for preparing composition as claimed in claim 1, it is characterised in that comprise the following steps：In proportion will
Berberine hydrochloride, dyclonine hydrochloride are dissolved in aqueous solution of propylene glycol, stirring to whole dissolvings, plus purified water, adjust Ph values,
Plus purified water, it is filling to produce after stirring.
4. method as claimed in claim 2, it is characterised in that Ph regulations, Ph=2.0-4.0 are carried out using hydrochloric acid.
5. application of the pharmaceutical composition as claimed in claim 1 in preventing and treating dog duct inflammation.
6. application as claimed in claim 5, it is characterised in that including following steps：Lift have sharp ears, obtained by extruding
Composition 2-4 times, makes decoction be full of duct；Vertical pressing duct for several times, can hear that the liquid sound is preferred, is then inhaled with paper
Take the liquid and dirt of floating.
7. pharmaceutical composition as claimed in claim 1 is in the preventing and treating dermopathic application of dog.
8. application as claimed in claim 7, it is characterised in that including following steps：Hair is separated, liquid medicine jet is being suffered from
On portion's skin, to complete wetting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710285398.1A CN107260731A (en) | 2017-04-27 | 2017-04-27 | One kind is used to prevent and treat dog duct inflammation, dermopathic pharmaceutical composition and its application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710285398.1A CN107260731A (en) | 2017-04-27 | 2017-04-27 | One kind is used to prevent and treat dog duct inflammation, dermopathic pharmaceutical composition and its application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107260731A true CN107260731A (en) | 2017-10-20 |
Family
ID=60073595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710285398.1A Pending CN107260731A (en) | 2017-04-27 | 2017-04-27 | One kind is used to prevent and treat dog duct inflammation, dermopathic pharmaceutical composition and its application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107260731A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453172A (en) * | 2018-12-26 | 2019-03-12 | 湖北中博绿亚生物技术有限公司 | Pharmaceutical composition, preparation method and its application |
-
2017
- 2017-04-27 CN CN201710285398.1A patent/CN107260731A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109453172A (en) * | 2018-12-26 | 2019-03-12 | 湖北中博绿亚生物技术有限公司 | Pharmaceutical composition, preparation method and its application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1137685C (en) | Non-irritation, non-sensitizing non-ototoxic otic antibacterial compositions | |
| WO2017101790A1 (en) | Pharmaceutical composition for treating cutaneous pruritus and use thereof | |
| WO2018064978A1 (en) | Uses of bacteriostatic agent formula in preparing composition for vaginal use and composition for vaginal use | |
| NO326139B1 (en) | Composition comprising a plant chemical concentrate of Echinacea purpurea and benzalkonium chloride. | |
| CN107405360B (en) | Novel iodophor compositions and methods of use thereof | |
| WO2020114166A1 (en) | Chloroquine gel and preparation method and application therefor | |
| CN104224923A (en) | Tea tree essential oil antimicrobial gel for treating vaginal disease in gynecology | |
| WO2011088745A1 (en) | Ophthalmic external antibacterial medicine | |
| DE102009003942A1 (en) | Use of deuterium oxide for the treatment of virus-based diseases of the eye | |
| WO2013029525A1 (en) | Pharmaceutical composition comprising iodine polymer and glucocorticosteroid for treating dermatitis | |
| US9662356B1 (en) | Propolis-metal nanoparticle composition and methods of use | |
| CN105582383A (en) | Composition containing alkannin and lemon grass essential oil | |
| CN103006561B (en) | Lipofectin nanometer silver gel and preparation method thereof | |
| CN107519236A (en) | A kind of topical agent for treating onychomycosis | |
| CN107260731A (en) | One kind is used to prevent and treat dog duct inflammation, dermopathic pharmaceutical composition and its application | |
| CN101278908A (en) | Eye drop capable of significantly increasing medicament effect | |
| CN104288222A (en) | Nano-medicine for treating dairy cow endometritis and preparation method of nano-medicine | |
| CN109464621A (en) | A kind of external preparation and preparation method thereof for treating eczema | |
| CN102920656A (en) | Moxifloxacin nanoemulsion and its preparation method | |
| CN104224802B (en) | A kind of moxifloxacin hydrochloride auristilla and preparation method thereof | |
| CN108653701A (en) | A kind of herbal mixture essential oil composition of analgesic and its preparation method of preparation | |
| CN101757119B (en) | Medicine composition for treating vaginitis as well as gel and preparation method thereof | |
| CN110193017B (en) | Film spraying agent for promoting hair growth and preparation method thereof | |
| EP4129314A1 (en) | Use of dandelion and monomer compounds thereof for killing mites | |
| CN102526121A (en) | Wound repair composition and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20171020 |
|
| WD01 | Invention patent application deemed withdrawn after publication |